title: Imatinib: a designer drug, another cutaneous complication.
abstract: A 55-year-old man with a history of mild psoriasis was started on imatinib for chronic myeloid leukaemia. He developed new nail dystrophy after treatment with an exacerbation of his psoriasis. Although not a contraindication for this drug, it should be remembered that psoriasis may worsen with imatinib.
authors.affiliation: Department of Haematology, Heatherwood and Wexham Park NHS Foundation Trust, Wexham Park Hospital, Slough, UK.
authors.forename: E
authors.initials: E
authors.lastname: Dickens
authors.forename: F
authors.initials: F
authors.lastname: Lewis
authors.forename: N
authors.initials: N
authors.lastname: Bienz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011565:Psoriasis / Q000139:chemically induced*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate